Healthcare Industry News: myelodysplastic syndromes
News Release - September 5, 2013
Otsuka Pharmaceutical to Acquire Astex PharmaceuticalsTOKYO--(Healthcare Sales & Marketing Network)--Otsuka Pharmaceutical Co., Ltd. is pleased to announce an agreement with Astex Pharmaceuticals, Inc. (“Astex”) to acquire Astex via an all-cash tender offer. The total purchase price of $866 million is based on the treasury stock calculation method and a tender offer of US $8.50 per share for all outstanding common shares.
Objectives of the Acquisition
Otsuka aims to enhance its discovery and development of drugs with novel working mechanisms by combining Astex’s fragment-based drug discovery technology with Otsuka’s own R&D strengths in areas such as central nervous system diseases. The fragment-based discovery technology, named PYRAMID™, is one of the most significant new drug discovery platforms of the past two decades and holds significant promise to bring new therapies more quickly to awaiting patients and physicians. Otsuka will also strengthen its promising oncology development portfolio and inline oncology offerings.
Dr. Taro Iwamoto, Otsuka Pharmaceutical's President and Representative Director, remarked, "I hope that this acquisition of Astex will strengthen not only our cancer portfolio but also our drug discovery research in the central nervous system field, through the acquisition of Astex's fragment-based drug design technology. Astex's unique fragment-based drug discovery technology and clinical oncology research and development capabilities, born out of the passion of its researchers, exemplify our corporate mottos and belief in "Sozosei (Creativity) and Jissho (Proof through Execution). I would like Otsuka Pharmaceutical to continue to respect Astex's uniqueness and leverage it to bring further growth for Otsuka Pharmaceutical."
About Astex Pharmaceuticals, Inc.
Astex is a bio-venture company established in 1991, with a fragment-based drug discovery research center in Cambridge, England and a clinical research and development function in California. Fragment-based discovery technology enables more rapid discovery and development of compounds for target proteins implicated in diseases than has heretofore been possible with high-throughout screening. Simply described, this technology evaluates binding of target proteins with small molecules via 3D structural analysis. As a result, in the past 8 years Astex has advanced 8 new compounds to the clinical R&D stage in the fields of oncology and the central nervous system. Four of these are in phase-2 clinical trials, including SGI-110 a novel DNA methylation inhibitor and AT13387, an inhibitor of heat shock protein 90 (HSP90) which are involved in the reproduction of cancer cells, and four are in phase-1 trials. Four of these compounds are undergoing clinical trials in several partnerships.
Astex achieved the development and launch of Dacogen®, a drug that treats myelodysplastic syndromes and elderly acute myeloid leukemia. Dacogen® (decitabine) has worldwide sales of approximately $280 million and is presently sold by Eisai Inc. in North America and by Janssen in other regions.
About Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The chairman Akihiko Otsuka is the third generation of Otsuka family members to lead the business, whose origins date from 1921. The Otsuka Group has business operations in 25 countries and regions around the world, with consolidated sales of approximately USD 13 billion for fiscal year 2012 (4/1/2012-3/31/2013). Otsuka welcomes you to visit its global website at https://www.otsuka.co.jp/en/.
Source: Otsuka Pharmaceutical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.